Patents Examined by Michael Barker
  • Patent number: 10449204
    Abstract: The present invention relates to a method for maintaining normoglycemia in a mammal in need thereof, preferably a critically ill patient suffering from acute stress, and to a method for preventing or limiting renal ischemia-reperfusion (I/R) in a mammal, preferably in a critically ill patient suffering from acute stress.
    Type: Grant
    Filed: March 6, 2012
    Date of Patent: October 22, 2019
    Assignee: CFM PHARMA HOLDING BV
    Inventors: Hendrik Jan Cornelis, Lekhram Changoer
  • Patent number: 10449206
    Abstract: A group of indolealkylamino-withasteroid conjugates, isolated and purified from Withania somnifera, are described. A synthetic method of making an indolealkylamino-withasteroid compound is provided. In vitro acetyl cholinesterase inhibitory activity and methods for treatment of dementia and dementia-related disorders, such as Alzheimer's disease, and anxiety and depressive disorders in mammals are demonstrated with these novel compositions.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: October 22, 2019
    Assignee: Natreon, Inc.
    Inventors: Shibnath Ghosal, Muruganandam Veeraragavan, Sanyasi R. Kalidindi
  • Patent number: 10428095
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: October 1, 2019
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Xiangzhu Wang, Dawei Chen, Akihiro Hashimoto, Venkat Rao Gadhachanda, Godwin Pais, Qiuping Wang, Atul Agarwal, Milind Deshpande
  • Patent number: 10426809
    Abstract: The present invention involves the isolation of plant based CNCs from the leaves of S. cumini. For the formation of NCs, a novel greener approach using S. cumini LE as reducing agent for in situ impregnation of AgNPs as fillers into CNCs as matrix is reported. The silver nitrate solution in three different concentrations of 1 mM, 5 mM and 10 mM was used to form NCs where AgNPs have been incorporated into CNCs matrix. The CNCs and NCs were characterized using SEM, TEM, XRD, Zeta potential, FT-IR, and UV-Vis spectroscopy. NCs developed in the form of film and ointment showed strong antimicrobial activity against both gram negative and gram positive bacteria. NCs wound dressing is capable of regulating wound exudates and providing moisture to wound responsible for faster healing of acute wounds. The observations from histopathological and biochemical assays confirmed that NCs enhance healing because of lesser inflammation, rapid angiogenesis, early collagen formation and enhanced rate of reepithelization.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: October 1, 2019
    Assignee: Council of Scientific & Industrial Research
    Inventors: Sudesh Kumar Yadav, Rubbel Singla, Avnesh Kumari
  • Patent number: 10426803
    Abstract: A composition and method for treating Epidermolisis bullosa (EB), comprising: applying to skin or mucosal surfaces of a patient in need of treatment for EB a dressing gauze or bandage without prior cleaning of said skin or mucosal surfaces, wherein distributed on said dressing is an effective amount of a composition containing beeswax; an oleaginous base, vitamins and a pharmaceutically acceptable excipient; then removing said dressing at least twice per day without damaging the patient's skin or mucosal surfaces due to removal of the dressing.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: October 1, 2019
    Assignee: REV PHARMA CORP
    Inventor: Efrain Ramon Vasquez
  • Patent number: 10426807
    Abstract: The invention relates to a bone and joint protection composition and use thereof. According to the composition, the four Chinese medicinal herbs Eucommiae Cortex, Achyranthis Bidentatae Radix, Astragali Radix and Chuanxiong Rhizoma are used, and the effects of enhancing the bone density, preventing and relieving osteoporosis, restraining the activity of osteoclast, promoting the function of bone cells, increasing the formation of calcified bone, promoting cartilage repair, delaying joint recession and repairing joint damage are achieved through multiple approaches and multiple levels. On the basis, by adding glucosamine hydrochloride, chondroitin sulfate and/or collagen, the bone density can be enhanced, the osteoporosis can be prevented and treated; the activity of the osteoclast can be restrained, the function of bone cells can be promoted, the formation of calcified bone can be increased, the cartilage repair can be promoted, joint recession can be delayed, and the joint damage can be repaired.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: October 1, 2019
    Assignee: INFINITUS (CHINA) COMPANY LTD.
    Inventors: Bin Shi, Xiaolei Guo, Chung Wah Ma, Wei Zhang, Zhen Luo
  • Patent number: 10428078
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: October 1, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
  • Patent number: 10398740
    Abstract: An object of the present invention is to provide: a Tau protein production accelerator containing a natural product as an active ingredient; a therapeutic or preventive agent for a disease caused by Tau protein deficiency; and a therapeutic or preventive food composition for a disease caused by Tau protein deficiency. Provided are: a Tau protein production accelerator containing a dry powder, ground product and/or extract of an earthworm as an active ingredient; a therapeutic or preventive agent for a disease caused by Tau protein deficiency; and a therapeutic or preventive food composition for a disease caused by Tau protein deficiency. The disease caused by Tau protein deficiency is preferably Alzheimer's disease.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: September 3, 2019
    Assignee: WELL STONE CO.
    Inventors: Yoichi Ishii, Takayuki Nemoto, Takeshi Okamoto
  • Patent number: 10398776
    Abstract: A phonophoretic cannabidiol composition comprises an amount of cannabidiol, an amount of a glucose source, such as honey, an amount of aloe vera, and amounts of one or more of glucosamine, methylsulfonylmethane, and chondroitin. A transdermal delivery system for administration of a phonophoretic cannabidiol composition includes a phonophoretic cannabidiol composition, a laser generator comprising an emitter which generates and directs a laser beam to the treatment area, and an ultrasound generator comprising a transducer which generates and transmits a plurality of ultrasonic waves to the treatment area. A method for transdermal delivery of a phonophoretic cannabidiol composition includes selecting laser pretreatment parameters, directing a laser beam to the treatment area, applying an amount of a phonophoretic cannabidiol composition to a treatment area, selecting ultrasonic treatment parameters, and, transmitting a plurality of ultrasonic waves to the treatment area.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: September 3, 2019
    Assignee: Essential Green Goodness LLC
    Inventors: Shamaya Chah, Nicholas Bart Magrone, Sr.
  • Patent number: 10391070
    Abstract: Provided are compounds for the treatment of neurological diseases or injuries, including neurodegenerative diseases, stroke, trauma, epilepsy, acute and chronic kidney injuries, diabetes mellitus, and/or seizures. In some embodiments, derivatives of vitamin K are provided.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: August 27, 2019
    Assignee: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: C. James Chou, Sherine S. Chan, Jennifer J. Rahn, Benjamin J. Josey
  • Patent number: 10392349
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: August 27, 2019
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Scott Kuduk
  • Patent number: 10383910
    Abstract: The present disclosure relates to a method of increasing fertility of a male subject, wherein the male subject suffers from reduced fertility resulting from a medication, wherein the medication inhibits sperm cell production by inhibiting spermatogenesis in a testis of the male subject, and wherein the method comprises administering to the male subject an effective amount of an extract of Costus speciosus in combination with the medication to prevent, and/or reduce the inhibition of sperm cell production by the medication to increase the fertility of the male subject.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: August 20, 2019
    Assignee: King Abdulaziz University
    Inventors: Dalia Mostafa Mohammed Domiaty, Sherifa Shaker Hamed Hassaballa
  • Patent number: 10383899
    Abstract: An improved method for the manufacture of a medicament, which method includes the use of tissues, larval forms or derivatives of insects that have been fed on food containing pathogens.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: August 20, 2019
    Assignee: MMUNE MACRO-BIOTIC TECHNOLOGY UK LIMITED
    Inventor: Christopher Jeremy Leonard
  • Patent number: 10376537
    Abstract: Disclosed herein is a method of reducing the risk of a rhinovirus infection, the method includes administering to a subject a composition comprising iota-carrageenan in an antiviral effective amount as an active antiviral ingredient.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: August 13, 2019
    Assignee: MARINOMED BIOTECH AG
    Inventors: Andreas Grassauer, Eva Prieschl-Grassauer, Christiane Koller, Alexander Pretsch
  • Patent number: 10376577
    Abstract: Disclosed herein is a refined product obtained from a rice hull, which consists essentially of a type II arabinogalactan having a number average molecular weight in the range of 56 to 103 kDa. Also disclosed are a process for producing the refined product and use of the refined product for enhancing the biological activity of innate immune cells, as well as for treating allergy and cancer.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: August 13, 2019
    Assignee: China Medical University
    Inventors: Wen-Chuan Lin, Li-Chan Yang, Chang-Chi Hsieh
  • Patent number: 10364236
    Abstract: Compounds, and compositions, methods, and uses thereof, are described herein for treating neurodegenerative diseases and disorders. In particular, vasopressin receptor modulators, and compositions, methods and uses thereof, are described herein for treating neuropsychiatric aspects of neurodegenerative diseases such as Huntington's Disease, Parkinson's Disease, and Alzheimer's Disease.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: July 30, 2019
    Assignee: Azevan Pharmaceuticals, Inc.
    Inventor: Michael J. Brownstein
  • Patent number: 10363277
    Abstract: Rhinoceros horn analogs and methods of synthesis thereof. Compounds with medicinal effects can be incorporated into the analogs. Genetic fingerprints can also be incorporated into the analogs. The analogs can be formulated into compositions.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: July 30, 2019
    Assignee: Pembient, Inc.
    Inventors: George A. Bonaci, Matthew Markus
  • Patent number: 10342837
    Abstract: The present invention relates to extracts from Helichrysum odoratissimum for use in the prevention of and treatment of skin cancer. The invention also provides for pharmaceutical compositions containing the extract and to the use of medicaments containing the extract.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: July 9, 2019
    Assignee: University of Pretoria
    Inventors: Danielle Twilley, Namrita Lall
  • Patent number: 10342835
    Abstract: The present invention relates to a composition for promoting proliferation of bone marrow derived stem cells using an angelicae gigantis radix extract, and more particularly, to a composition which administers a granulocyte colony-stimulating factor into an object, and administers the angelicae gigantis radix extract to the object to promote the proliferation of the bone marrow derived stem cells. The composition of the present invention solves side effects such as splenomegaly which were caused by a method of administering only the G-CSF for proliferation and differentiation of the stem cells, thereby significantly mitigating the side effects through co-administration of the angelicae gigantis radix extract, and further promoting the proliferation and the differentiation of the stem cells.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: July 9, 2019
    Assignee: COMPREHENSIVE AND INTEGRATIVE MEDICINE INSTITUTE
    Inventors: Chang Hyeong Lee, Sang Gyung Kim, Im Hee Shin, Seung Mo Kim, Joon Seok Byun, Ki Cheul Sohn, Sae Kwang Ku
  • Patent number: 10343994
    Abstract: The invention relates to the compounds of formula I, formula II, formula III, formula IV and formula V or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV or formula V and methods for the treatment of inflammation and pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of pain, oral mucosal inflammatory or oral infectious diseases.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: July 9, 2019
    Inventor: Mahesh Kandula